Next Article in Journal
Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia
Previous Article in Journal
Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 1
10.3747/co.25.4006
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Meeting Report

Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma

by
C. Owen
1,
J. Kuruvilla
2 and
A. Christofides
3,*
1
Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada
2
Department of Medicine, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON, Canada
3
Impact Medicom Inc., Toronto, ON M6S 3K2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(1), 83-90; https://doi.org/10.3747/co.25.4006
Submission received: 1 November 2017 / Revised: 1 December 2017 / Accepted: 1 January 2018 / Published: 1 February 2018

Abstract

The 2017 annual meeting of the American Society of Hematology took place 9–12 December in Atlanta, Georgia. At the meeting, results from key studies in the treatment of relapsed and refractory mantle cell lymphoma were presented. Of those studies, oral presentations focused on the efficacy and safety of therapy with Bruton tyrosine kinase (BTK) inhibitors. One study presented pooled data from three trials using ibrutinib, with a median follow-up of 3.5 years. A second phase ii study presented data on the efficacy and safety of acalabrutinib, a highly selective BTK inhibitor with minimal off-target activity. The final study presented early phase ib data on the efficacy and safety of zanubrutinib, a novel, highly selective BTK inhibitor, in patients with non-Hodgkin lymphoma. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice.
Keywords: relapsed disease; refractory disease; mantle cell lymphoma relapsed disease; refractory disease; mantle cell lymphoma

Share and Cite

MDPI and ACS Style

Owen, C.; Kuruvilla, J.; Christofides, A. Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma. Curr. Oncol. 2018, 25, 83-90. https://doi.org/10.3747/co.25.4006

AMA Style

Owen C, Kuruvilla J, Christofides A. Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma. Current Oncology. 2018; 25(1):83-90. https://doi.org/10.3747/co.25.4006

Chicago/Turabian Style

Owen, C., J. Kuruvilla, and A. Christofides. 2018. "Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma" Current Oncology 25, no. 1: 83-90. https://doi.org/10.3747/co.25.4006

APA Style

Owen, C., Kuruvilla, J., & Christofides, A. (2018). Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma. Current Oncology, 25(1), 83-90. https://doi.org/10.3747/co.25.4006

Article Metrics

Back to TopTop